Display options
Cite
Derakhshandeh-Rishehri SM, Heidari-Beni M, Eftekhari MH. THE EFFECTS OF REALSIL (SILYBIN-PHOSPHOLIPID-VITAMIN E COMPLEX) ON LIVER ENZYMES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) OR NON-ALCOHOLIC STEATO-HEPATITIS (NASH): A SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS. Acta Endocrinol (Buchar). 2020;16(2):223-231doi: 10.4183/aeb.2020.223.
Derakhshandeh-Rishehri, S. M., Heidari-Beni, M., & Eftekhari, M. H. (2020). THE EFFECTS OF REALSIL (SILYBIN-PHOSPHOLIPID-VITAMIN E COMPLEX) ON LIVER ENZYMES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) OR NON-ALCOHOLIC STEATO-HEPATITIS (NASH): A SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS. Acta endocrinologica (Bucharest, Romania : 2005), 16(2), 223-231. https://doi.org/10.4183/aeb.2020.223
Derakhshandeh-Rishehri, S M, et al. "THE EFFECTS OF REALSIL (SILYBIN-PHOSPHOLIPID-VITAMIN E COMPLEX) ON LIVER ENZYMES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) OR NON-ALCOHOLIC STEATO-HEPATITIS (NASH): A SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS." Acta endocrinologica (Bucharest, Romania : 2005) vol. 16,2 (2020): 223-231. doi: https://doi.org/10.4183/aeb.2020.223
Derakhshandeh-Rishehri SM, Heidari-Beni M, Eftekhari MH. THE EFFECTS OF REALSIL (SILYBIN-PHOSPHOLIPID-VITAMIN E COMPLEX) ON LIVER ENZYMES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) OR NON-ALCOHOLIC STEATO-HEPATITIS (NASH): A SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS. Acta Endocrinol (Buchar). 2020 Apr-Jun;16(2):223-231. doi: 10.4183/aeb.2020.223. PMID: 33029240; PMCID: PMC7535884.
Copy Download .nbib Format: NLM
Share it on

Acta Endocrinol (Buchar). 2020 Apr-Jun;16(2):223-231. doi: 10.4183/aeb.2020.223.

THE EFFECTS OF REALSIL (SILYBIN-PHOSPHOLIPID-VITAMIN E COMPLEX) ON LIVER ENZYMES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) OR NON-ALCOHOLIC STEATO-HEPATITIS (NASH): A SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS.

Acta endocrinologica (Bucharest, Romania : 2005)

S M Derakhshandeh-Rishehri, M Heidari-Beni, M H Eftekhari

Affiliations

  1. Shiraz University of Medical Sciences, Shiraz, Fars, Iran.
  2. Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.

PMID: 33029240 PMCID: PMC7535884 DOI: 10.4183/aeb.2020.223

Abstract

BACKGROUND: The aim of the present study was to systematically review the effects of Realsil (silybin-phospholipid-vitamin E complex) on liver enzymes in patients with NAFLD or NASH.

METHODS: We searched Web of Science, MEDLINE, Google Scholar, Cochrane Library, Science Direct, ProQuest, Scopus, and 1868 articles were found up to December 2018. Four studies that examined the effect of Realsil intake on liver enzymes among NAFLD or NASH patients were included. Exclusion criteria include: animal studies, studies with the design other than clinical trials, studies on non-adult individuals, studies that assess the effect of vitamin E, silybin, or phospholipid solely, studies that examined the effect of Realsil on other outcomes, or studies with insufficient data.

RESULTS: The analysis demonstrated that Realsil intake led to a significant decrease in Gamma-Glutamyl Transpeptidase (GGT) levels (standardized mean difference (SMD) =-0.37; 95% confidence interval (CI]): -0.68 to -0.06). Realsil intake non-significantly decrease alanine transaminase (ALT) levels (SMD=-1.02 U/L; 95% CI: -2.23 to 0.20) and non-significantly increase aspartate aminotransferase (AST) levels (SMD = 0.17 U/L; 95% CI: -0.26-0.61).

CONCLUSION: Realsil intake was associated with a significantly decreased circulating GGT level without any significant effect on AST and ALT levels.

©by Acta Endocrinologica Foundation.

Keywords: Alanine Transaminase; Aspartate Aminotransferases; Silybin; gamma-Glutamyltransferase; vitamin E

References

  1. Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112 - PubMed
  2. Minerva Gastroenterol Dietol. 2005 Jun;51(2):193-9 - PubMed
  3. Hepatology. 2007 Nov;46(5):1387-91 - PubMed
  4. Clin Liver Dis. 2009 Nov;13(4):511-31 - PubMed
  5. J Phys Chem A. 2008 Feb 7;112(5):1054-63 - PubMed
  6. Dig Dis. 2010;28(1):155-61 - PubMed
  7. World J Hepatol. 2013 Mar 27;5(3):109-13 - PubMed
  8. Dig Dis Sci. 2005 Jan;50(1):171-80 - PubMed
  9. Dis Markers. 2015;2015:818570 - PubMed
  10. Eur Rev Med Pharmacol Sci. 2015 Aug;19(16):3118-24 - PubMed
  11. Hepat Mon. 2012 Aug;12(8):e6099 - PubMed
  12. Semin Liver Dis. 2008 Nov;28(4):339-50 - PubMed
  13. Org Biomol Chem. 2003 May 21;1(10):1684-9 - PubMed
  14. Int J Mol Sci. 2016 Aug 23;17(9): - PubMed
  15. In Vivo. 2017 Jul-Aug;31(4):609-618 - PubMed
  16. Dig Liver Dis. 2010 Apr;42(4):272-82 - PubMed
  17. Cardiovasc Diabetol. 2011 Jul 14;10:62 - PubMed
  18. Am J Gastroenterol. 2003 Nov;98(11):2348-50 - PubMed
  19. Clin Mol Hepatol. 2015 Dec;21(4):379-86 - PubMed
  20. Mediators Inflamm. 2014;2014:750860 - PubMed
  21. Nutr Metab (Lond). 2009 Jul 30;6:30 - PubMed
  22. Free Radic Biol Med. 2012 May 1;52(9):1658-65 - PubMed
  23. J Hepatol. 2013 Oct;59(4):859-71 - PubMed
  24. Expert Rev Gastroenterol Hepatol. 2015 Apr;9(4):519-27 - PubMed
  25. Nutrients. 2018 Aug 23;10(9): - PubMed
  26. Intern Emerg Med. 2019 Jan;14(1):77-84 - PubMed
  27. N Engl J Med. 2010 May 6;362(18):1675-85 - PubMed
  28. Curr Pharm Des. 2010;16(7):814-24 - PubMed
  29. Diabetologia. 2008 Sep;51(9):1616-22 - PubMed
  30. Aliment Pharmacol Ther. 2013 Jul;38(2):134-43 - PubMed
  31. Diabetol Metab Syndr. 2019 Feb 4;11:12 - PubMed
  32. Aliment Pharmacol Ther. 2001 Sep;15(9):1239-52 - PubMed
  33. Rev Esp Enferm Dig. 2018 Oct;110(10):634-640 - PubMed
  34. J Pediatr. 1999 Feb;134(2):160-5 - PubMed
  35. J Pediatr Gastroenterol Nutr. 2009 May;48(5):587-96 - PubMed
  36. Dig Liver Dis. 2006 Nov;38(11):789-801 - PubMed
  37. World J Gastroenterol. 2011 May 14;17(18):2288-301 - PubMed
  38. Clin Res Hepatol Gastroenterol. 2012 Apr;36(2):146-55 - PubMed
  39. Oxid Med Cell Longev. 2014;2014:169216 - PubMed

Publication Types